Evidence map›Paper›PMID 41857394›Full record

Trial reportNature immunology2026

Improved VSV-Ebola-GP booster vaccination approach promotes antibody affinity maturation and durable anti-Ebola immunity in humans.

Surender Khurana, Olivia Posadas, Lela Kardava, Elizabeth M Coyle, Supriya Ravichandran, Gabrielle Grubbs, Rosemary McConnell, Nadine Rouphael, Guillaume Poliquin, Joanne M Langley and 6 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Surender KhuranaDivision of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA. surender.khurana@fda.hhs.gov.ORCID http://orcid.org/0000-0002-0593-7965
Olivia PosadasDivision of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA.
Lela KardavaLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-9135-6026
Elizabeth M CoyleDivision of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA.
Supriya RavichandranDivision of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA.
Gabrielle GrubbsDivision of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA.
Rosemary McConnellCritical Care Medicine, Clinical Research Center, National Institutes of Health, Bethesda, MD, USA.
Nadine RouphaelHope Clinic of the Emory Vaccine Center, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-2512-7919
Guillaume PoliquinPublic Health Agency of Canada, Children's Hospital Research Institute, Winnipeg, Manitoba, Canada.
Joanne M LangleyCanadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia, Canada.ORCID http://orcid.org/0000-0003-3270-7345
Eric ChuBiostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Dean A FollmannBiostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Xiaoran ShangDepartment of Microbiology and Immunology, Center for Biomolecular Therapeutics, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-3986-4557
Yuxing LiDepartment of Microbiology and Immunology, Center for Biomolecular Therapeutics, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-9785-2960
Susan Moir *Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-0163-6911
Richard T Davey *Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Funding

ODCDC CDC HHS HHSN272200700016IUnited States Department of Defense | Defense Threat Reduction Agency (DTRA) HDTRA1930447U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) 75N910D00024U.S. Department of Health & Human Services | U.S. Food and Drug Administration (U.S. Food & Drug Administration) Medical Countermeasures initiative (MCMi) OCET 2020-1355
6 · The paper itself

Abstract

Short-term boosting of the currently licensed rVSV∆G-ZEBOV-GP vaccine does not generate lasting antibody respones to Ebola virus (EBOV), prompting interest in strategies that elicit more durable immunity. Here, we elucidated the longitudinal humoral immune repertoire over 3 years following prime and boost rVSV∆G-ZEBOV-GP vaccinations administered 18 months apart in healthy adults compared to participants randomized to no boost. This delayed booster vaccination induced long-lasting EBOV-neutralizing antibodies that persisted up to 36 month at levels similar to peak titers after a single dose. Phage display libraries, expressing linear and conformational epitopes of EBOV glycoprotein (GP), demonstrated a highly diverse and durable antibody epitope repertoire following prime boost vaccination. Delayed booster vaccination recalled memory B cells, promoted anti-GP IgG class switching and induced antibodies specific to GP with Fcγ receptor interaction and functional antibody-dependent cellular cytotoxicity and phagocytosis. The 18-month interval led to 13-fold higher antibody affinity maturation than a single dose, maintained up to 36 months. Overall, delayed rVSV∆G-ZEBOV-GP booster vaccination promoted a diverse, stronger, durable, predominant IgG, highly affinity-matured antibody response to GP.

Indexed as

Antibodies, ViralEbola VaccinesEbolavirusHemorrhagic Fever, EbolaAdultAntibodies, NeutralizingAntibody AffinityAntibody-Dependent Cell CytotoxicityEpitopesFemaleHumansImmunization, SecondaryImmunoglobulin GMaleVaccinationYoung AdultAntibodies, NeutralizingAntibodies, ViralEbola VaccinesEpitopesImmunoglobulin G

Identifiers

PMID41857394
PMCPMC13132720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.